Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG100

MILPITAS Calif. Jan. 5 2017 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today announced that a key patent has issued covering orally stable peptides from the company's most advanced development program. This new U.S. patent No. 9518091 together w...